Perioperative Treatment Outcomes of Early NSCLC (Peri-R)

Shanghai Jiao Tong University

Status: Invitation-only

Conditions: NSCLC

Study type: Observational

Funder types: Other

Identifiers

NCT06610240

IS24118

Details and patient eligibility

About

This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes of perioperative NSCLC patients receiving different treatment strategies. According to the inclusion and exclusion criteria, perioperative NSCLC patients admitted to the study center from January 1, 2020, to one year after the study initiation will be retrospectively screened and collected.

Enrollment: 500 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stage I-III NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.
• Patients who have undergone radical lung cancer surgery.
• Patients who have received neoadjuvant treatment before radical lung cancer surgery, including chemotherapy, targeted therapy, or immunotherapy both alone or combined.

Exclusion criteria

• Patients with other previous malignancies, except those who achieved complete remission at least two years before radical lung cancer surgery and did not require additional treatment.
• Patients with incomplete key baseline and treatment information，including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant.
• Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.
• Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.